Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dipyridamole increases human red blood cell deformability.

A R Saniabadi1, T C Fisher, C S Lau

  • 1Institute of Biomedical Sciences, Terumo Shonan Centre, Kanagawa, Japan.

European Journal of Clinical Pharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of CXCL10 release by monomeric C3bi and C4b.

Clinical and experimental immunology·2011
Same author

A rare case of ovarian carcinoid causing heart failure.

Scottish medical journal·2011
Same author

The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Clinical and experimental immunology·2010
Same author

A platelet counting technique to study platelet aggregation in whole blood: application to pathologically low platelet counts.

Platelets·2010
Same author

Effective inhibition of platelet aggregation in whole blood with a combination of dipyridamole and iloprost.

Platelets·2010
Same author

Therapeutic apheresis from the early civilizations to the twenty-first century.

Gastroenterologie clinique et biologique·2010

Dipyridamole (DP) improves red blood cell deformability in patients with chronic renal failure on hemodialysis (HD) and peripheral vascular disease (PVD). This suggests DP may help improve microvascular perfusion when red cell rigidity is a factor.

Area of Science:

  • Hematology
  • Cardiovascular Science
  • Biomedical Engineering

Background:

  • Red blood cell (RBC) rigidity is implicated in microvascular perfusion impairments.
  • Patients with chronic renal failure (CRF) on hemodialysis (HD) and peripheral vascular disease (PVD) often exhibit reduced RBC deformability.

Purpose of the Study:

  • To investigate the effect of dipyridamole (DP) on RBC deformability in patients with rigid red cells.
  • To assess DP's potential to improve microvascular perfusion.

Main Methods:

  • Automated filtration technique using Imugard wool and Nuclepore Hemafil Membranes (4.7 microns).
  • Measured initial steady-state relative filtration pressure (iRFP) to assess RBC deformability.
  • Tested RBCs from controls, PVD patients, and HD patients with and without 5 microM DP.

Related Experiment Videos

Main Results:

  • Patients with PVD and HD showed significantly higher iRFP values (more rigid RBCs) compared to controls.
  • DP significantly reduced iRFP values in all groups, indicating increased RBC deformability.
  • DP decreased iRFP from 0.393 to 0.278 in PVD patients and from 0.403 to 0.263 in HD patients.

Conclusions:

  • Dipyridamole enhances red blood cell deformability.
  • DP may offer therapeutic benefits in conditions characterized by red cell rigidity and impaired microvascular perfusion, such as PVD and CRF.